查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1557318

自我血糖監測設備 (SMBG) 的全球市場 - 2024 年至 2029 年預測

Global Self-Monitoring Blood Glucose (SMBG) Devices Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

自我血糖監測設備（SMBG）市場預計將從2024年的116.44億美元成長到2029年的158.83億美元，成長率為6.41%（CAGR）。

自我血糖監測 (SMBG) 裝置可監測一個人的血糖濃度。高血糖和低血糖都會對人體產生嚴重影響，因此定期檢查是必要的。糖尿病是一種慢性疾病，會破壞人體分泌胰島素的能力，對整體健康和其他器官的功能產生負面影響。

由於複雜、壓力大的生活方式和工作文化導致不良的飲食習慣，糖尿病病例數量不斷增加，因此有必要定期檢查體內的胰島素，特別是對於患有糖尿病的人來說。 SMBG 設備是可攜式、快速的合成設備，可在幾分鐘內提供血液中的血糖濃度，因此在監測血糖方面得到更廣泛的採用。

市場技術進步在推動市場成長方面也發揮著重要作用。此外，醫療保健支出的增加預計將推動市場。

自我血糖監測設備（SMBG）市場促進因素：

  • 由於生活方式複雜化和飲食攝取不準確，糖尿病患者數量不斷增加，推動了市場的成長。

試紙和血糖儀等自我血糖測量設備在改善患者代謝控制和藥物治療方面發揮重要作用，可以清楚地了解患者的血糖狀況。此外，SMBG 設備提供的必要資訊將幫助醫生了解患者的飲食攝取量以及根據健康狀況開出哪些藥物。

根據國際糖尿病聯盟預測，到2030年，全球將有近6.43億人患有糖尿病，到2045年，全球將有近7.83億人患有糖尿病。

隨著糖尿病人口的驚人成長，自我血糖監測設備的需求預計在未來幾年將強勁成長。這在新興經濟體尤其明顯，這些低度開發國家，刺激了整體市場的擴張。

  • 宣傳糖尿病意識的宣傳活動和舉措

糖尿病是全世界主要的健康問題之一，會引起與眼睛、腳和腎臟相關的各種健康問題。因此，正在實施各種健康宣傳活動和政府支持的舉措，以減少此類疾病的傳播。例如，2023 年 2 月，紐約州衛生部發起了一項宣傳宣傳活動，鼓勵在西班牙裔和黑人社區進行糖尿病前期檢測。

同樣，根據 2024 年 6 月 7 日的新聞稿，英格蘭國家醫療服務體系宣布，將於 6 月 10 日起在西米德蘭茲郡舉辦糖尿病宣傳週。此類措施和宣傳活動可能會將人們的注意力轉移到自我監測血糖水平上，並增加對 SMBG 設備的需求。

自我血糖監測設備（SMBG）市場細分分析

  • 試紙預計將佔據重要的市場佔有率

根據產品類型，全球自助血糖儀市場分為血糖儀、試紙、採血針和採血筆。另一方面，試紙是一次性的、一次性使用的試紙，上面放置有血液，以便可以將其注射到血糖儀中。試紙由於是一次性的而佔據了很大的市場佔有率。

血糖儀是一種電子設備，它使用透過試紙注入的血液樣本來計算和顯示血糖值。因此，它在市場上佔有很大的佔有率。

  • 據估計，2 型糖尿病佔了很大的市場佔有率。

根據指示，全球自我血糖儀市場分為第 1 型糖尿病、2 型糖尿病和妊娠糖尿病。由於 2 型糖尿病在成年人中很常見，並且在各個國家都有很高的盛行率，因此預計其將顯著成長並在該疾病中佔據很大佔有率。根據美國疾病管制與預防中心 2023 年 11 月發布的新聞稿，超過三分之一的美國成年人有罹患第 2 型糖尿病的風險。

預計北美在預測期內將佔據重要的市場佔有率。

從地理來看，SMBG設備市場分為北美、南美、歐洲、中東和非洲以及亞太地區。預計北美地區在預測期內將以有利的速度成長，美國和加拿大等主要區域經濟體的糖尿病盛行率不斷上升，導致自我血糖監測設備的採用激增。

預計該地區可支配收入的增加和醫療保健支出的增加也將在預測期內推動市場。北美和歐洲的自我血糖測量設備市場預計將佔據主要市場佔有率。

自我血糖監測設備（SMBG）市場的限制因素

  • 自我監測血糖設備的高成本阻礙了市場的成長。

血糖自我監測設備市場面臨的主要限制之一是設備的高成本。自我血糖監測設備包括血糖儀、試紙、採血針和採血器。該設備的初始成本很高。此外，該設備還具有試紙的經常性成本，因為試紙是一次性的且不能重複使用。此類工具的高昂成本可能會限制低收入和中等收入國家的市場。

開拓自我血糖監測設備（SMBG）的主要市場

  • 2023年3月，Asterra Pharma 與 Roche Diabetes Care Japan K.K. 建立合作關係。 2023年3月，Asterra Pharma Co., Ltd.與Roche Diabetcare Japan Co., Ltd.合作開發了一款產品，結合了該公司的血糖儀「Accu-Check® Guide M」與FDA核准的數字健康解決方案「BluStar」 」。我們已經開始在日本市場開發和銷售該產品。

2022 年 11 月，Intuity Medical Inc. 和 Embecta Corp. 簽訂了共同促銷協議。 Envector 將利用其經銷商在美國市場促銷Intuity 的 POGO 自動血糖監測系統。該產品旨在改善糖尿病管理。

自我血糖監測設備（SMBG）市場細分分析如下：

按類型

  • 血糖儀
  • 試紙
  • 採血針和採血筆

按指示

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

按最終用戶

  • 醫院和診所
  • 門診護理設置
  • 診斷中心
  • 居家照護設置

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 其他
  • 中東/非洲
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 其他
  • 亞太地區
  • 中國
  • 印度
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 日本
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第 5 章按類型分類的全球自我血糖監測設備 (SMBG) 市場

  • 介紹
  • 血糖值儀
  • 試紙條
  • 採血針和採血裝置

第6章按適應症分類的自我血糖監測設備（SMBG）的全球市場

  • 介紹
  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第7章全球自我血糖監測設備 (SMBG) 市場：依最終用戶分類

  • 介紹
  • 醫院和診所
  • 門診就診環境
  • 診斷中心
  • 家庭護理設置

第 8 章按地區分類的全球自我血糖監測設備 (SMBG) 市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 日本
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Abbott
  • Hoffmann-La Roche Ltd.
  • Lifescan Inc.
  • Bayer Corporation
  • ARKRAY, Inc.
  • B. Braun Melsungen AG
  • Sanofi
  • Ypsomed AG
  • Bionime Corporation
  • Ascensia Diabetes Care Holdings AG
簡介目錄
Product Code: KSI061612026

The global self-monitoring blood glucose (SMBG) devices market is anticipated to grow from US$11.644 billion in 2024 to US$15.883 billion in 2029 at a 6.41% (CAGR).

A self-monitoring blood glucose (SMBG) device monitors a person's glucose level. Both high and low blood glucose have the potential to severely impact the human body and hence require regular checks. Diabetes is a chronic disease that results in a disturbance in the body's insulin production, negatively impacting overall health and other organs' functioning.

The rising cases of diabetes owing to complex & stressful lifestyles and work cultures that have disturbed the dietary intake of people have created the requirement of recurring insulin checks in the body, especially for those suffering from the disease. SMBG devices are portable, faster, result-yielding devices that provide the glucose level in the blood within a few minutes and hence have witnessed a wider adoption for monitoring glucose.

Technological advancements in the market also play a vital role in encouraging market growth. Furthermore, increasing healthcare expenditures are expected to drive the market.

Global Self-Monitoring Blood Glucose (SMBG) Devices Market Drivers:

  • Growing cases of diabetes owing to lifestyle complexities and inaccurate dietary intake have increased the market growth.

Self-monitoring blood glucose devices such as testing strips or glucose meters play an integral in improving a patient's metabolic control, and medication regime and provide a clear picture of their glycemic status. Furthermore, the necessary information provided by the SMBG devices assists doctors in understanding the patient's diet intake and what medications are to be prescribed as per their health status.

Diabetes has been emerging as a problematic chronic disease causing a great threat to life, according to the International Diabetes Federation, by 2030 nearly 643 million people will be living with diabetes globally and by 2045 it will be nearly 783 million.

With the alarming growth of the diabetic population, the demand for self-monitoring blood glucose devices is expected to show massive growth in the coming years. This can be witnessed especially in developed economies, where disposable income is higher than in underdeveloped nations, stimulating the overall market expansion.

  • Favorable campaigns and initiatives to spread awareness against diabetes

One of the major health concerns globally, diabetes leads to various other health problems related to the eyes, feet, and kidneys. Hence, various health campaigns and government-backed initiatives are being implemented to reduce the spread of such diseases. For instance, in February 2023, the New York State Department of Health launched a public awareness campaign to encourage Hispanic and black communities for prediabetic tests.

Likewise, as per the 7 June 2024 press release, the National Health Service England announced diabetic awareness week in West Midland from 10 June, during which the healthcare system will educate people regarding symptoms, risks, and prevention associated with Type 1 and Type 2 diabetes. Such initiatives and campaigns will shift the focus of people towards self-glucose monitoring thereby driving the demand for SMBG devices.

Global Self-Monitoring Blood Glucose (SMBG) Devices Market Segment Analysis

  • Testing strips are expected to account for a considerable market share.

Based on product type, the global self-monitoring blood glucose device market is segmented into blood glucose meters, testing strips, and lancets & lancing devices. Testing strips, on the other hand, are disposable, one-time-use strips on which blood is placed so that it can be injected into the blood glucose meter. Since testing strips are single-use, they account for a remarkable market share.

Blood glucose meters are electronic devices that calculate and display blood glucose levels using a sample of blood drops injected through a testing strip. Hence, they have a significant share of the market.

  • Type 2 diabetes is estimated to account for a considerable market share.

Based on indication, the global self-monitoring blood glucose device market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. Type 2 diabetes is poised for remarkable growth and will constitute a remarkable share as such diseases are found more commonly in adults and have a high prevalence in countries. According to the November 2023 press release of the Center for Disease Control and Prevention, more than 1 in 3 American adults are at risk of developing type 2 diabetes.

North America is predicted to constitute a considerable market share during the forecast period.

Geographically, the SMBG device market is divided into North America, South America, Europe, the Middle East, Africa, and the Asia Pacific regions for the study. North America is expected to grow at a lucrative rate during the forecasted period, fuelled by the growing prevalence of diabetes in major regional economies, namely the United States and Canada, which has surged the adoption of self-monitoring blood glucose devices.

Rising disposable income and increasing expenditure on healthcare in the region are also expected to drive the market during the forecast period. The North American and European self-monitoring blood glucose device markets are projected to hold a large market share.

Global Self-Monitoring Blood Glucose (SMBG) Devices Market Restraints

  • The high associated cost of self-monitoring blood glucose devices will hinder market growth.

One of the prime constraints facing the self-monitoring blood glucose device market is the significant cost of the device. Self-monitoring blood glucose devices involve blood glucose meters, testing strips, and lancets and lancing devices. The initial cost of this device is significant. Furthermore, the device has a recurring cost of testing strips since these strips are single-use and cannot be reused. The notable cost of such a device has the potential to constrain the market in lower-middle and lower-income countries.

Global Self-Monitoring Blood Glucose (SMBG) Devices Key Market Developments

  • In March 2023, Astella Pharma Inc. partnered with Roche Diabetes Care Japan Co. Ltd to bolster the development & commercialization of the former's "Accu-Chek(R) Guide M" blood glucose monitoring system as a combined product with FDA-approved digital health solution "BluStar" in the Japanese market.

In November 2022, Intuity Medical Inc. and Embecta Corp. formed a co-promotional agreement. The latter would use its sales representatives to promote Intuity's "POGO Automatic(R) Blood Glucose Monitoring System" in the US market. The product aims to improve people's diabetes management.

The Global Self-Monitoring Blood Glucose (SMBG) Devices market is segmented and analyzed as follows:

By Type

  • Blood Glucose Meters
  • Testing Strips
  • Lancets & Lancing Device

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

By End-User

  • Hospitals and Clinics
  • Ambulatory Care Settings
  • Diagnostics Centers
  • Home Care Settings

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Blood Glucose Meter
  • 5.3. Testing Strips
  • 5.4. Lancets & Lancing Devices

6. GLOBAL SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY INDICATION

  • 6.1. Introduction
  • 6.2. Type 1 Diabetes
  • 6.3. Type 2 Diabetes
  • 6.4. Gestational Diabetes

7. GLOBAL SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Ambulatory Care Settings
  • 7.4. Diagnostics Centers
  • 7.5. Home Care Settings

8. GLOBAL SELF-MONITORING BLOOD GLUCOSE (SMBG) DEVICES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. South Korea
    • 8.6.4. Taiwan
    • 8.6.5. Thailand
    • 8.6.6. Indonesia
    • 8.6.7. Japan
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott
  • 10.2. Hoffmann-La Roche Ltd.
  • 10.3. Lifescan Inc.
  • 10.4. Bayer Corporation
  • 10.5. ARKRAY, Inc.
  • 10.6. B. Braun Melsungen AG
  • 10.7. Sanofi
  • 10.8. Ypsomed AG
  • 10.9. Bionime Corporation
  • 10.10. Ascensia Diabetes Care Holdings AG